|
|
Eric Lazartigues, PhD
Assistant Professor of Pharmacology
1901 Perdido St.
Box P7-1
New Orleans, LA 70112
Phone: (504) 568-3210
Fax: (504) 568-2361
elazar@lsuhsc.edu
Lab webpage
|
| Degrees |
BS Physiology - 1993
University Pail Savatier Toulouse III, France
MS Cardiovascular Pharmacology - 1994
University Claude Bernard Lyon I, France
PhD Cardiovascular Pharmacology - 1999
University Paul Sabatier - Doctoral School of Toulouse, France
|
| Bio |
Dr. Eric Lazartigues, Assistant Professor, received his Bachelor of Sciences in 1993 from University Paul Sabatier of Sciences in Toulouse, France. His Master of Sciences was awarded in 1994 from the University of Pharmacy Claude Bernard of Lyon, France. He received his PhD from University Paul Sabatier of Sciences in Toulouse in 1999. He completed his postdoctoral work at The University of Iowa School of Medicine in the Department of Anatomy & Cell Biology. Dr. Lazartigues joined the department of Pharmacology at LSU Health Sciences Center in August 2005.
Peer and International Recognition
- Member of the Editorial Board of The American Journal of Physiology-Integrative and Comparative Physiology, 2008
- Member of the Award Committee of The American Physiological Society, 2008-2010
- Elected Fellow of The American Heart Association, 2006
- Merck New Investigator Award from the American Heart Association High Blood Pressure Research Council, 2005
- Van Harreveld Memorial Award from The American Physiological Society CNS section, 2005
- Neural Control and Autonomic Regulation Recognition Award for Meritorious Research by a Young Investigator from The American Physiological Society, 2004
- Neural Control and Autonomic Regulation New Investigator Award from The American Physiological Society, 2003
- Servier Distinguished Young Investigator Award, 2001
|
| Research Interests |
Angiotensin-II (Ang-II) exerts its profound cardiovascular (CV) and volume homeostatic properties through activation of specific receptors, primarily Ang-II type 1 (AT1), located both in the periphery and in the brain. Evidence has shown the importance of the brain renin-angiotensin system (RAS) in the maintenance of normal blood pressure (BP) and in the development of hypertension. Although, new genetic and pharmacological tools have improved our understanding of the global functioning of this system, the role of its different components and their interactions remain poorly understood due to the difficulty in experimentally dissecting brain versus peripheral RAS. Recently, a new element of the RAS, named ACE2, has been identified and is believed to degrade Ang-II to the vasodilator peptide angiotensin-1-7 (Ang1-7).
Very recently, we identified the presence of ACE2 in the brain and our interests focus on the role of this enzyme in modulating the activity of the brain RAS during the development of neurogenic hypertension. Using non-transgenic (NT) and genetically-engineered mice in combination with molecular, physiological, and pharmacological tools, our laboratory is dedicated in assessing the relative physiological significance of central ACE2 in normal and pathophysiological regulation of BP and other CV diseases.
|
| Teaching Activities |
2007-present Cell Signaling and Cell Cycle – Drug-receptor interactions module I (PHARM 207); lecturer
2007-present Principles of Pharmacology II, (PHARM 206). Animal models of disease: Hypertension; lecturer
2007-present Special topics in Physiology: Physiological Reviews (PHYSIO 280); group discussion facilitator
2008-present Nursing Pharmacology (HLSC 3409); lecturer
2008-present Advanced Nursing Pharmacology (HLSC 6409); Course co-Director
2009-present Pharmacology Seminar (PHARM 298 & 299); Course co-Director
|
| Selected Publications |
- Xia H., Feng Y., Obr T.D., Hickman P.J. & Lazartigues E. AT1 receptor-mediated reduction of ACE2 activity in the brain impairs baroreflex function in hypertensive mice.Hypertension, 2009; 53(2):210-216.
- Stewart J.A., Lazartigues E. & Lucchesi P.A. The ACE2/Ang-(1-7) axis in the Heart: A role for Mas Communication? (Editorial) Circ Res, 2008; 103(11):1197-1199.
- Xia H. & Lazartigues E. Angiotensin converting enzyme 2 in the brain: properties and future directions. (Invited Review) J Neurochem, 2008; 107:1482-1494.
- Bindom S.M. & Lazartigues E. The Sweeter Side of ACE2: Physiological Evidence for a Role in Diabetes. (Invited Review) Mol Cell Endocrinol, 2008 Oct 1 [Epub ahead of print].
- Feng Y., Yue X., Xia H., Bindom S.M., Hickman P.J., Filipeanu C.M., Wu G. & Lazartigues E. ACE2 over-expression in the subfornical organ prevents the Angiotensin-II-mediated pressor and drinking responses and is associated with AT1 receptor down-regulation.Circ Res, 2008; 102(6):729-736.
- Lazartigues E., Feng Y. & Lavoie J.L. The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. (Invited Review) Curr Pharm Design, 2007; 13:1231-1245.
- Doobay M.F., Talman, L.S., Obr T.D., Tian, X., Davisson R.L. & Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin angiotensin system.Am J Physiol Regul Integr Comp Physiol, 2007; 292(1):R373-R381.
|
